STOCK TITAN
  1. Home
  2. News
  3. AVXL

Anavex Life Sciences - AVXL STOCK NEWS

Welcome to our dedicated page for Anavex Life Sciences news (Ticker: AVXL), a resource for investors and traders seeking the latest updates and insights on Anavex Life Sciences stock.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for neurodegenerative and neurodevelopmental disorders. Headquartered in New York, Anavex focuses on precision medicine to treat diseases with high unmet medical needs, such as Alzheimer's disease, Parkinson's disease, Rett syndrome, and schizophrenia.

Anavex's lead compound, ANAVEX 2-73 (blarcamesine), is an orally available small molecule targeting sigma-1 and muscarinic receptors. It aims to restore cellular homeostasis, showing promise in multiple CNS disorders. Blarcamesine has successfully completed Phase 2a and Phase 2b/3 trials for Alzheimer's disease and various studies in Rett syndrome, including a recent Phase 2/3 EXCELLENCE pediatric trial demonstrating significant improvements in Rett Syndrome Behaviour Questionnaire (RSBQ) scores.

The company also has other promising drug candidates, such as ANAVEX 3-71, targeting sigma-1 and M1 muscarinic receptors. This candidate has exhibited disease-modifying activity in Alzheimer's disease models and is currently in a Phase 2 trial for schizophrenia.

Anavex actively engages in partnerships and collaborations, including support from the Michael J. Fox Foundation for Parkinson's Research. With a robust intellectual property portfolio, Anavex is committed to advancing its pipeline through rigorous clinical trials to bring effective treatments to market.

Recent highlights include presenting at key industry conferences and filing a Marketing Authorisation application with the European Medicines Agency (EMA) for blarcamesine in Alzheimer's disease. Anavex also recently bolstered its executive team with seasoned professionals to drive its R&D and clinical strategies forward.

For more information, visit www.anavex.com or follow the company on Twitter, Facebook, Instagram, and LinkedIn.

News

Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update

Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) reported financial results for its fiscal year ended September 30, 2023, with key pipeline updates for Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and more. The company also highlighted recent business and financial highlights, including the grant of a new patent, initiation of a Marketing Authorisation application, and appointment of a new Senior Vice President. The company's cash and cash equivalents stood at $151.0 million at September 30, 2023, with a net loss of $10.1 million for the fourth quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.04%
Tags
earnings
-
News

Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023

Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) will issue financial results for its fiscal year ended September 30, 2023, on November 27, 2023. The company is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative and neurodevelopmental disorders. A conference call will be held to review financial results and provide an update on the execution of the Company’s growth strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.52%
Tags
earnings
-
News

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Insomnia or Anxiety

Rhea-AI Summary
Anavex Life Sciences Corp. (AVXL) announced the grant of U.S. Patent No. 11,813,242 entitled 'A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY, AND AGITATION.' This patent expands the company's existing patent coverage of ANAVEX®2-73 (blarcamesine), ANAVEX®1-41, and ANAVEX®19-144 for treating insomnia, anxiety, and agitation. The patent is expected to remain in force until July 2037, providing extensive coverage for the company's lead compounds. Anavex aims to deliver holistic care for patients with Alzheimer’s dementia or Parkinson’s diseases, who often concurrently suffer from insomnia and/or anxiety.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
News

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency (EMA)

Rhea-AI Summary
Anavex Life Sciences Corp. (Nasdaq: AVXL) met with the European Medicines Agency to discuss blarcamesine (ANAVEX®2-73) Alzheimer’s disease clinical program results. Anavex initiated the process for submitting a Marketing Authorisation application to the EMA for oral blarcamesine. The goal is to allow direct access to the European Union market for the treatment of Alzheimer’s disease. An estimated 7 million people in Europe have Alzheimer’s disease, with costs of care estimated at $439 billion in 2019. Anavex aims to provide convenient oral treatment options for Alzheimer’s patients, addressing the urgent need for simple patient-centered administrations and shared decision-making.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.64%
Tags
none
-
News

Anavex Life Sciences Appoints Senior VP of Regulatory Affairs

Rhea-AI Summary
Anavex Life Sciences Corp. has appointed David Goldberger as Senior Vice President Regulatory Affairs. Goldberger brings over 40 years of experience in pharmacy practice and the pharmaceutical industry, with expertise in regulatory strategies and global interactions for CNS development projects. He will succeed Emmanuel O Fadiran, who is retiring. Goldberger has previously led regulatory efforts for CNS products at Otsuka Pharmaceuticals and Johnson and Johnson. Anavex is a clinical-stage biopharmaceutical company focused on developing therapeutics for neurodegenerative and neurodevelopmental disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
management
-
News

Anavex Life Sciences Reports New Publication in Scientific Journal Demonstrating the Potential of ANAVEX®3-71 to Prevent Cognitive Decline in Alzheimer’s Disease

Rhea-AI Summary
Anavex Life Sciences Corp. has reported a new study that shows the potential disease-modifying properties of ANAVEX®3-71 (AF710B) in Alzheimer's disease. The study found that ANAVEX®3-71 treatment prevented cognitive decline and reduced amyloid and neuroinflammation in a transgenic rat model of Alzheimer's disease. The drug candidate could be a promising option for a once daily oral preventive strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.97%
Tags
none
News

Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration

Rhea-AI Summary
Anavex Life Sciences Corp. announces significant reduction in amyloid beta biomarkers of Alzheimer's pathology in Phase 2b/3 study with blarcamesine (ANAVEX®2-73)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
clinical trial
-
News

Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board

Rhea-AI Summary
Anavex appoints Prof. Dr. Marwan N Sabbagh as Chairman of Scientific Advisory Board
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News

Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results

Rhea-AI Summary
Anavex Life Sciences Corp. reports financial results for Q2 2023 and provides pipeline updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.56%
Tags
earnings
News

Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming ANAVEX®3-71 Clinical Cardiovascular Safety

Rhea-AI Summary
Anavex Life Sciences Corp. announced positive findings from the ANAVEX®3-71 first-in-human study, achieving its cardiovascular safety objectives. The study evaluated the effect of ANAVEX®3-71 on ECG parameters and demonstrated no clinically relevant effects. This supports the drug's development program, including its potential use in Schizophrenia, Frontotemporal Dementia, and Alzheimer's Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.57%
Tags
none

FAQ

What is the current stock price of Anavex Life Sciences (AVXL)?

The current stock price of Anavex Life Sciences (AVXL) is $8.63 as of December 20, 2024.

What is the market cap of Anavex Life Sciences (AVXL)?

The market cap of Anavex Life Sciences (AVXL) is approximately 711.4M.

What is Anavex Life Sciences Corp's primary focus?

Anavex Life Sciences Corp focuses on developing novel therapeutics for neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease, Parkinson's disease, Rett syndrome, and schizophrenia.

What is ANAVEX 2-73?

ANAVEX 2-73 (blarcamesine) is Anavex's lead drug candidate. It targets sigma-1 and muscarinic receptors to restore cellular homeostasis and has shown promise in treating various CNS disorders.

What recent results were obtained from Anavex's trials?

Recent trials for ANAVEX 2-73 in Rett syndrome showed significant improvements in Rett Syndrome Behaviour Questionnaire (RSBQ) scores. The company is also progressing in trials for Alzheimer's disease and schizophrenia with ANAVEX 3-71.

What partnerships does Anavex Life Sciences have?

Anavex partners with several organizations, including the Michael J. Fox Foundation for Parkinson's Research, which supports the development of ANAVEX 2-73 for Parkinson's disease.

What are Anavex's recent business highlights?

Recent highlights include presenting at key industry conferences, filing a Marketing Authorisation application with the European Medicines Agency (EMA) for blarcamesine in Alzheimer's disease, and strengthening the executive team.

Where is Anavex Life Sciences headquartered?

Anavex Life Sciences is headquartered in New York, USA.

How can I stay updated on Anavex Life Sciences' developments?

You can stay updated by visiting their website at www.anavex.com and following their social media profiles on Twitter, Facebook, Instagram, and LinkedIn.

What is the significance of ANAVEX 3-71?

ANAVEX 3-71 targets sigma-1 and M1 muscarinic receptors, showing disease-modifying activity in Alzheimer's disease models. It is currently in a Phase 2 trial for schizophrenia.

What makes Anavex Life Sciences' approach unique?

Anavex uses precision medicine to develop therapeutics based on genomic data, aiming to address high unmet medical needs in CNS disorders.

Who are the recent additions to Anavex's executive team?

Recent additions include Dr. Juan Carlos Lopez-Talavera as Senior VP of Research and Development, Dr. Terrie Kellmeyer as Senior VP of Clinical Development, and Dr. Jeffrey Edwards as VP of Clinical Pharmacology and Science.

Stock AVXL logo
Anavex Life Sciences

Nasdaq:AVXL

AVXL Rankings

#2811 Ranked by Market Cap
N/A Ranked by Dividends

AVXL Stock Data

711.43M
82.21M
3.05%
32.08%
22.18%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
NEW YORK